Literature DB >> 1662997

Withdrawal of immunosuppressive therapy in allogeneic bone marrow transplantation reactivates chronic viral hepatitis C.

F S Fan1, C H Tzeng, K I Hsiao, S T Hu, W T Liu, P M Chen.   

Abstract

A 28-year-old female patient with acute myelogenous leukemia and post-transfusion chronic viral hepatitis C received an allogeneic bone marrow transplantation (BMT) in first complete remission. The inflammatory activity of chronic hepatitis C decreased dramatically with the start of BMT and during the whole course of cyclosporin A treatment. After the immunosuppressive therapy was stopped, however, the chronic hepatitis C activity increased and the serum alanine amino-transferase levels thereafter remained as high as before BMT. Hepatitis C virus RNA was detected by polymerase chain reaction in serum drawn 60 days and 52 months after BMT. Since fulminant viral hepatitis B may take place after tapering of immunosuppressive therapy following BMT due to an excessive response of recovering immunity to the actively replicating virus during immune suppression, careful monitoring of liver function for patients with chronic viral hepatitis C in BMT is suggested.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662997

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  12 in total

Review 1.  Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.

Authors:  Harrys A Torres; Marta Davila
Journal:  Nat Rev Clin Oncol       Date:  2012-01-24       Impact factor: 66.675

Review 2.  Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups.

Authors:  H L Tillmann; M P Manns
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 3.  2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-08-10

Review 4.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

5.  Transcription factors linked to the molecular signatures in the development of hepatocellular carcinoma on a cirrhotic background.

Authors:  Jamshid Motalebzadeh; Elaheh Eskandari
Journal:  Med Oncol       Date:  2021-09-01       Impact factor: 3.064

6.  Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.

Authors:  Takeaki Takenaka; Kuniaki Itoh; Takayo Suzuki; Atae Utsunomiya; Shin Matsuda; Takaaki Chou; Toshiaki Sai; Masayuki Sano; Susumu Konda; Tatsuji Ohno; Chikara Mikuni; Kijoh Deura; Takashi Yamada; Fumi Mizorogi; Haruhisa Nagoshi; Masao Tomonaga; Tomomitsu Hotta; Kohichi Kawano; Keitaro Tsushita; Masami Hirano; Masanori Shimoyama
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

Review 7.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

8.  Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients.

Authors:  D Sansonno; A R Iacobelli; V Cornacchiulo; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

9.  Hepatitis B and C in hematopoietic stem cell transplant.

Authors:  Anna Locasciulli; Barbara Montante; Emanuela Morelli; Virginia Gulino; Anna Proia; Maria Beatrice Pinazzi
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-03       Impact factor: 2.576

10.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2014-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.